Drug Profile
Golimumab biosimilar - Harvest Moon Pharmaceuticals
Latest Information Update: 17 Nov 2021
Price :
$50
*
At a glance
- Originator Harvest Moon Pharmaceuticals
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antiasthmatics; Antihyperglycaemics; Antirheumatics; Cardiovascular therapies; Eye disorder therapies; Monoclonal antibodies
- Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Immunological disorders